Vernalis Research Limited

Vernalis &r&d) Ltd.

Gemma Caroline Stratton

Roger John Gillespie

Joanne Lerpiniere

Suneel Gaur

Scott Murray Weiss

Stefania Leonardi

Samantha Jayne Bamford

Allan Michael Jordan

Richard Simon Todd

Claire Elizabeth Dawson

Robert Mark Pratt

Compounds of formula (I); wherein Ris H or NHZ; Ris optionally substituted aryl or heteroaryl attached via a carbon atom; Ris H; optionally substituted C-Calkyl, C-Calkenyl, C-Calkynyl, or CCcycloalkyl, halogen; OH or OR, or Ris H, optionally substituted C-Calkyl, CCalkenyl, C-Calkynyl, C-Ccycloalkyl, aryl or heteroaryl, Ris H or optionally substituted C-Calkyl, C-Calkenyl, C-Calkynyl, or C-Ccycloalkyl; or Rand Rtogether form a 5 or 6-membered heterocyclic ring; and Ris optionally substituted C-Calkyl; are purine receptor, particularly adenosine receptor antagonists, useful for treatment of, inter alia, movement disorders such as Parkinsons disease. 

Pyrimidine compounds as purine receptor antagonist

The use of a compound of formula (I): wherein

Triazol[4,5-d] pyramidine derivatives and their use as purinergic receptor antagonists

Use of a compound of formula (I) wherein Ris selected from alkyl, aryl, alkoxy, aryloxy, 0thioalkyl, thioaryl, CN, halo, NRR, NRCOR, NRCONRR, NRCORand NRSOR; Ris selected from N, O or S-containing heteroaryl groups, wherein the heteroaryl group is attached via an unsaturated carbon atom which is adjacent to one or two N, O or S-heteroatom(s), other than ortho, ortho-disubstituted heteroaryl groups; Ris selected from H, alkyl, COR, CONRR, CONRNRR, CORand SOR; R, Rand Rare independently selected from H, alkyl and aryl or where Rand Rare in an (NRR) group then Rand Rmay be linked to form a heterocyclic ring; Ris selected from alkyl and aryl; R, Rand Rare independently selected from H, alkyl and aryl, or Rand Rmay be linked to form a heterocyclic ring, or where R, Rand Rare in a (CONRNRR) group, Rand Rmay be linked to form a heterocyclic group; and R, is selected from alkyl and aryl, or a pharmaceutically acceptable salt thereof or prodrug thereof, in the treatment or prevention of a disorder in which the blocking of purine receptors, particularly adenosine receptors and more particularly Areceptors, may be beneficial, particularly wherein said disorder is a movement disorder such as Parkinson's disease or said disorder is depression, cognitive or memory impairment, acute or chronic pain, ADHD or narcolepsy, or for neuroprotection in a subject; compounds of formula (I) for use in therapy; and novel compounds of formula (I) per se. 

Purine derivatives as purinergic receptor antagonists

Triazolo [4,5-d] pyrimidine derivatives and their use as purinergic receptor antagonists

The use of a compound of formula (I): wherein Ris selected from H, alkyl, aryl, alkoxy, aryloxy, alkylthio, arylthio, halogen, CN, NRR, NRCONR, NRCONRR,NRCORand NRSOR; Ris selected from aryl attached via an unsaturated carbon; Ris selected from H, alkyl, COR, COR, CONRR, CONRNRRand SOR; R, Rand Rare independently selected from H, alkyl and aryl or where Rand Rare in an NRRgroup, Rand Rmay be linked to form a heterocyclic group, or where R, Rand Rare in a (CONRNRR) group, Rand Rmay be linked to form a heterocyclic group; and Ris selected from alkyl and aryl, or a pharmaceutically acceptable salt thereof or prodrug thereof, in the treatment or prevention of a disorder in which the blocking of purine receptors, particularly adenosine receptors and more particularly Areceptors, may be beneficial, particularly wherein said disorder is a movement disorder such as Parkinson's disease or said disorder is depression, cognitive or memory impairment, acute or chronic pain, ADHD or narcolepsy, or for neuroprotection in a subject; compounds of formula (I) for use in therapy; and novel compounds of formula (I) per se 

Triazolo[4,5-d]pyrimidine derivatives and their use as purinergic receptor antagonists

Growing community of inventors

Wokingham, United Kingdom

Gemma Caroline Stratton